Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and is accompanied by skin manifestations of psoriasis. The disease combines elements of both arthritis and skin pathology, often causing inflammation and damage to the joints, which can lead to functional impairment and limitation of mobility. PsA can occur in people with an established diagnosis of psoriasis, but it also happens that joint symptoms precede skin manifestations. There are many mechanisms involved in the pathogenesis of psoriatic arthritis, including immune and inflammatory processes, making it a subject of active study in the field of dermatology and rheumatology.
History of the disease and interesting historical facts
The pathology of psoriatic arthritis was first described in medical literature in the early 20th century. However, its history goes back much further, as serum links between psoriasis and arthritis were mentioned in ancient medical works. In the 1930s, the first scientific work was recorded devoted to clinical observations of patients suffering from both psoriasis and joint pain. It is interesting to note that in different eras and in different cultures, psoriasis was viewed differently: from “punishment from above” to “a disease of a famous person”. Only with the development of modern medicine did it become obvious that psoriatic arthritis is not a separate form of the disease, but one of the manifestations of systemic pathogenesis, which made it necessary to further study it and include it in the treatment program.
Epidemiology (statistics of disease occurrence)
Psoriatic arthritis has a high prevalence among patients with psoriasis, reaching 20-30% depending on the population and diagnostic criteria. According to a number of epidemiological studies, PsA affects approximately 0.3-1% of the general population. The disease occurs with equal frequency in men and women, although men have a more aggressive course. An important point is the age of onset of the disease: according to statistics, most patients first encounter manifestations of psoriatic arthritis between the ages of 30 and 50. However, recently there has been an increase in cases of the disease in younger age groups, which may be due to lifestyle changes and environmental factors.
Genetic predisposition to this disease
According to modern research, genetic predisposition to psoriatic arthritis exists and includes various genetic markers. One of the most studied is the main histoplasmic receptor HLA-B27, which is associated with various forms of inflammatory joint diseases. However, it is important to note that the presence of this gene does not guarantee the development of the disease, but only increases the risk. Other genes involved include IL-23R, TNF, and IL-17, which are involved in immune responses and inflammatory processes. Polymorphisms of these genes can affect the severity of the disease and its clinical manifestations. Research shows that the combination of genetic predisposition with environmental factors can significantly increase the likelihood of developing psoriatic arthritis.
Risk factors for the development of this disease
Risk factors that contribute to the development of psoriatic arthritis can be different and varied. The main ones are:
- Heredity: Having close relatives with psoriasis or psoriatic arthritis significantly increases the risk of developing the disease.
- Skin infections and injuries: these can serve as triggers for the development of psoriasis and, accordingly, its articular form.
- Alcohol consumption and smoking: Both of these factors can aggravate the course of the disease.
- Stress: psycho-emotional stress can provoke an exacerbation and the onset of the disease.
- Obesity: Being overweight is associated with a higher risk of developing both psoriasis and its articular form.
- Certain medications, such as beta blockers and some antimalarial drugs, may also trigger a flare-up of chronic inflammation.
Diagnosis of this disease
Diagnosis of psoriatic arthritis includes several stages and methods. The main symptoms indicating the presence of the disease are:
- Joint pain, especially when moving or in the morning.
- Morning stiffness lasting more than 30 minutes.
- Inflammatory changes in the joints, pain, swelling and redness.
- Skin manifestations such as psoriatic plaques, which may precede joint symptoms.
Laboratory tests may include a complete blood count, C-reactive protein, and tumor necrosis factor (TNF) antibodies. Radiological tests, such as joint X-rays and MRI, may reveal characteristic changes, including erosions and ossification. Other diagnostic tests may include serial observation of symptoms and skin examination. It is also important to differentiate other forms of arthritis, such as rheumatoid arthritis and osteoarthritis, to avoid misdiagnosis.
Treatment
Treatment of psoriatic arthritis requires a comprehensive approach and may include both conservative and surgical methods. As part of the overall treatment, it is important to remember the following points:
- Direct action on joint pain and inflammation through nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen.
- In severe forms of the disease, basic antirheumatic drugs (BADs) are prescribed: methotrexate, aceclafenac, and others.
- Biologic drugs such as tumor necrosis factor inhibitors (eg, adalimumab, etanercept) are becoming increasingly popular.
- Physical therapy, including exercise therapy and massage, can significantly improve patients' quality of life.
- Surgical intervention such as arthroplasty may be indicated in cases of severe joint destruction.
List of medications used to treat this disease
The following are used to treat psoriatic arthritis:
- Nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen, diclofenac.
- Basic antirheumatic drugs: methotrexate, leflundamide, cyclosporine.
- Biological drugs: adalimumab, etanercept, ustekinumab, secukinumab.
- Glucocorticosteroids: if necessary - prednisolone.
- Physiotherapy and supportive care to improve clinical condition.
Disease monitoring
Monitoring of psoriatic arthritis includes regular examinations by a rheumatologist or dermatologist, monitoring the functional state of the joints and assessing the activity of the disease. This allows for adjustment of therapy depending on the patient's condition. The prognosis depends on the asymptomatic state and the effectiveness of treatment; some patients may recover, while others may develop disability if inadequately treated. Complications may include erosive changes in the joints, which significantly impairs quality of life and requires active treatment.
Age-related features of the disease
Psoriatic arthritis can manifest itself in different age groups. In children and adolescents, the disease often has a more aggressive course and can be accompanied by systemic manifestations, which requires special attention from doctors. In adults, depending on gender and concomitant diseases, clinical manifestations can vary significantly. In elderly patients, the disease can be complicated by concomitant health problems, which complicates its treatment and management.
Questions and Answers
- What is psoriatic arthritis? Psoriatic arthritis is a chronic inflammatory disease that affects the joints and is associated with the skin manifestations of psoriasis.
- What are the main symptoms of psoriatic arthritis? The main symptoms include joint pain, morning stiffness, inflammation and redness of the joints, and psoriatic skin manifestations.
- How is psoriatic arthritis diagnosed? Diagnosis includes an analysis of symptoms, laboratory tests to determine inflammatory markers, and radiological studies to assess the condition of the joints.
- How is psoriatic arthritis treated? Treatment includes the use of NSAIDs, disease-modifying antirheumatic drugs, and biologics, as well as physical therapy if needed.
- What is the prognosis for patients with psoriatic arthritis? The prognosis varies depending on the severity of the disease and the adequacy of treatment; either complete recovery or the development of disability are possible.
